Advanced Cell Technology, Inc. (OTCMKTS:ACTC) Can’t Go Higher For Now

[[tagnumber 0]][[tagnumber 1]]Advanced Cell Technology, Inc. (OTCMKTS:ACTC) isn’t one of the cheapest stocks in the OTC markets, but attracts serious investor attention, despite its high price. Lately, [[tagnumber 2]]ACTC [[tagnumber 3]]has seen some major action.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]][[tagnumber 2]]ACTC [[tagnumber 3]]has quite the market cap, which currently sits at $237 million, but still has its trusted followers, despite the fact that the most recent report of the company shows it is not in very good financial state. Here are the numbers of prime interest from the second quarter of the year.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 13]] [[tagnumber 14]]cash: $4.06 million[[tagnumber 15]] [[tagnumber 14]]current assets: $4.59 million[[tagnumber 15]] [[tagnumber 14]]total assets: $5.54 million[[tagnumber 15]] [[tagnumber 14]]current liabilities: $9.44 million[[tagnumber 15]] [[tagnumber 14]]total liabilities: $11.38 million[[tagnumber 15]] [[tagnumber 14]]quarterly revenues: $39,469[[tagnumber 15]] [[tagnumber 14]]quarterly net loss: $15.51 million[[tagnumber 15]] [[tagnumber 28]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]These numbers put the company far from a [[tagnumber 2]]NASDAQ[[tagnumber 3]] listing, as the CEO of [[tagnumber 2]]ACTC[[tagnumber 3]], Mr. [[tagnumber 2]]Paul Wotton[[tagnumber 3]] has planned. Furthermore, judging by the major net loss that was recorded in the second quarter of the year, the company will have a hard time sustaining itself for long.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]Indeed, a major part of the liabilities for Q2 come from loss on settlement of litigation, but we saw some $8.68 million in net loss in Q1. This is more than twice the cash that [[tagnumber 2]]ACTC [[tagnumber 3]]has on hand and the only thing that can save them is toxic financing.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]This, [[tagnumber 2]]ACTC [[tagnumber 3]]has already done. Back in July, it was announced that [[tagnumber 2]]ACTC [[tagnumber 3]]have entered into a $30 million agreement with [[tagnumber 2]]Lincoln Park Capital Fund, LLC[[tagnumber 3]], an entity that many consider to be a provider of toxic funds.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]Lately, the company has had some optimistic news about the treatment of Stargardt’s macular degeneration and dry age–related macular degeneration and it has had some positive impact on the ticker. Unfortunately, they haven’t yet entered into Phase 2 clinical trials, which will take years to complete.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]Still, the optimistic news provided for a 16.69% jump in Tuesday’s session on a decent volume. The next session, however, was a dumping fiasco. Yesterday, [[tagnumber 2]]ACTC [[tagnumber 3]]gapped up at a massive $9.03 per share, more than $1 from the previous close, and as soon as that came around shares started flying around.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]It wasn’t surprising that the price quickly began to drop. By the end of the session more than 870 thousand shares changed their owners, but [[tagnumber 2]]ACTC [[tagnumber 3]]closed 3.51% below the previous day and generated a massive $7.21 million dollar volume.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]With such a high price and such a long period before eventually being able to operate at a profit, it is always good to do your due diligence and weigh out the risks before investing.[[tagnumber 4]]